Renaissance Capital logo

Adaptive Biotechnologies Priced, Nasdaq: ADPT

Provides genetic immunosequencing tests used to diagnose and treat diseases.

Industry: Health Care

First Day Return: +101.5%

Industry: Health Care

We are advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient’s immune system and understand precisely how it detects and treats disease in that patient. We capture these insights in our dynamic clinical immunomics database, which is underpinned by computational biology and machine learning, and use them to develop and commercialize clinical products and services that we are tailoring to each individual patient. We have two commercial products and services and a robust pipeline of clinical products and services that we are designing to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases.
more less
IPO Data
IPO File Date 05/30/2019
Offer Price $20.00
Price Range $18.00 - $19.00
Offer Shares (mm) 15.0
Deal Size ($mm) $300
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 06/26/2019
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $300
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters Seattle, WA, United States
Founded 2009
Employees at IPO 346
Website www.adaptivebiotech.com

Adaptive Biotechnologies (ADPT) Performance